By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is neutral on Pfizer's berobenatide, with key concerns being its inferior efficacy compared to competitors and the significant time gap before potential market entry.
Risk: Inferior efficacy and late entry may hinder Pfizer's ability to capture meaningful market share.
Opportunity: Monthly dosing could drive adherence and market share if real-world data supports significant compliance gains.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug market, to be sure. Lilly sold $13.5 billion worth of GLP-1-based Zepbound last year, while Novo reported revenue of more than $30 billion (U.S.) from its anti-obesity drugs Wegovy and Ozempic, with its weight loss arm experiencing year-over-year sales growth of more than 26%.
As is so often the case, though, would-be competitors aren't simply letting market leaders have unfettered access to a market that Morgan Stanley now believes will grow to a stunning $150 billion per year by 2035.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Drugmaker Pfizer (NYSE: PFE) is throwing its hat into the ring as well, recently offering a developmental update that should concern Novo Nordisk, Eli Lilly, and the shareholders of this weight-loss drug duopoly. Let's see what this could mean for all three companies.
It's called berobenatide. In many ways, it's like the aforementioned Wegovy and Zepbound, as it leverages the GLP-1 (glucagon-like peptide-1) receptor pathway to induce weight loss. And it's administered by subcutaneous injection.
There is one big way Pfizer's anti-obesity drug berobenatide -- also known as PF-08653944 -- differs from Wegovy, Ozempic, and Zepbound, though. That is, whereas Lilly's and Novo's treatments are injected weekly, Pfizer's GLP-1 receptor agonist requires only a monthly injection to achieve comparable weight-loss results.
That's what the developmental update, unveiled recently at the 86th Scientific Sessions of the American Diabetes Association, suggests, anyway. As the company's corresponding press release explains, the drug's phase 2b trials successfully "highlight the potential for monthly delivery in a patient-friendly presentation with a very low 0.5 mL injection volume that provides convenience and scalability advantages" for patients with or without type 2 diabetes. It's also about as well tolerated as alternatives.
There are some measurable trade-offs, of course. While this particular study showed a typical weight loss of 15.9% at the 32-week mark, patients might do slightly better with Novo Nordisk's or Eli Lilly's GLP-1 options as part of a clinically managed or carefully followed treatment regimen.
However, given that its average weight loss reflects a wide range of inputs that may or may not be affected by deviations from a dosing or diet regimen, some patients could conceivably achieve better personal results. Some observers also argue that berobenatide may produce better net weight loss in the long run simply because it's easier to stick to its corresponding weight-loss plan.
The trial's results also affirm the idea that this drug may be effective at maintaining a lower weight once a user's weight-loss goal has been met.
It's an obvious win for Pfizer. But even a late-phase 2b win for a single drug in its R&D pipeline isn't exactly game-changing for the company. There's still phase 3 testing to be done, which is not only time-consuming, but puts previous-stage results to the test on a wider scale. Veteran investors know all too well that the FDA can often spot something it doesn't like late in a drug's development that it didn't notice before.
Just understand that this same anti-obesity treatment -- berobenatide -- isn't just in one single mid-stage trial right now. It's currently undergoing a handful of similar trials as a weight-loss drug and a type 2 diabetes treatment, some of which are phase 3 trials -- the final stage before seeking regulatory approval. The market's already familiar with this drug and its safety profile. The recent update of its efficacy as a once-monthly, low-dose injection simply bolsters the overall optimism surrounding this drug, ultimately acquired with Pfizer's 2025 acquisition of drugmaker Metsera.
In a similar vein, Pfizer's update on phase 2b testing of low monthly doses of berobenatide gives the company another chance to tout that it actually has 10 different trials of this drug in or entering phase 3 by the end of this year. Moreover, it's got more than 20 anti-obesity treatments currently in the works at various stages of development.
Connect the dots. Pfizer is positioning to compete with Lilly and Novo. And it will be able to do so, even if only a handful of these trials meet their phase 3 targets.
Just keep your expectations in check. Multiple trials means multiple launches of the drug, each with a narrowly range of approved uses. Pfizer's obesity business will only build slowly and won't begin making major contributions to the top and bottom lines for at least a few years.
As CEO Albert Bourla commented in the company's recent Q1earnings conference call "Starting in 2029, we will enter a five-year period of high single-digit revenue CAGR," with much of its growth from that point on being driven by recent acquisitions like Matsera. The three years between now and then, however, are going to remain mostly unimpressive as the company continues to struggle with the sharp wind-down of its once-red-hot COVID-19 drug business.
The market has a funny way of predicting and reflecting those predictions in stock prices -- well in advance, though.
Whatever the case, even what's just moderately bullish for Pfizer is more bearish for Eli Lilly and Novo Nordisk. Pfizer is introducing competition to the weight-loss drug market, which is already seeing slowing growth. If nothing else, the eventual launch of berobenatide will further erode the already-waning pricing power of Wegovy, Ozempic, and Zepbound. And Pfizer isn't the only outfit working on an alternative anti-obesity drug either.
Given that Lilly and Novo shares have been priced at a premium largely on the potential of their weight-loss drugs, Pfizer's update is an important reminder that nothing lasts forever. Shareholders of either company will most definitely want to keep close tabs on the ongoing development of berobenatide. It's a brewing problem, to be sure.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $438,283! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,257,427!
Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 12, 2026. *
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Pfizer's update poses limited near-term risk to LLY and NVO given multi-year development timelines and unproven real-world advantages."
Pfizer's berobenatide phase 2b data shows 15.9% weight loss at 32 weeks with monthly 0.5mL dosing, but this remains years from potential approval. LLY's Zepbound generated $13.5B in 2024 while NVO's obesity portfolio exceeded $30B with 26%+ growth. The article understates that multiple phase 3 programs must succeed and that real-world adherence data is absent. Pricing power erosion for weekly GLP-1s is possible yet distant, as Pfizer's obesity revenue ramp is projected only after 2029 per CEO comments.
Monthly convenience could still drive superior long-term compliance and share gains if phase 3 confirms durability, potentially accelerating market fragmentation sooner than expected.
"Pfizer's berobenatide faces long regulatory, payer, and uptake hurdles that likely delay meaningful revenue, making near-term upside speculative."
Pfizer's berobenatide introduces a monthly GLP-1 option, a potentially meaningful differentiator on adherence. Yet the strongest risk to the bull case is timing: phase 3 trials, regulatory approval, and payer negotiation could push meaningful upside well beyond 2026–2027. Even with a favorable efficacy signal, the market is not forgiving of delays or post-approval safety reviews. The weight-loss arena is already a duopoly with Lilly and Novo leveraging deep payer access and robust pipelines; Pfizer would need multiple successful launches across indications to meaningfully move the top line. The analysis’s optimistic 2035 market size rests on many variables that could disappoint.
Even if phase 3 is clean, monetization could take years; safety concerns, supply or manufacturing constraints, or payer resistance could kill any early upside.
"Pfizer’s clinical progress in the GLP-1 space is secondary to the massive, multi-year manufacturing and distribution moat currently held by Eli Lilly and Novo Nordisk."
The market is overreacting to the 'monthly injection' narrative. While a once-monthly dosing schedule is a clear differentiator for Pfizer’s berobenatide, the article glosses over the brutal reality of the obesity drug landscape: it is a race for manufacturing scale, not just clinical efficacy. Eli Lilly (LLY) and Novo Nordisk (NVO) have already solved the 'cold chain' and supply chain logistics that Pfizer is years away from scaling. Even if berobenatide hits the market by 2027-2028, Pfizer faces a massive uphill climb to displace the entrenched duopoly. I remain neutral on PFE; the stock is a 'show me' story, and the revenue cliff from their COVID portfolio makes the wait for GLP-1 dominance too risky for current valuations.
If Pfizer’s monthly injection demonstrates superior patient adherence and lower side-effect profiles in Phase 3, it could force a rapid commoditization of the current weekly GLP-1 market, stripping LLY and NVO of their pricing power.
"Pfizer's berobenatide is a legitimate but late-stage entrant with inferior efficacy data and a 2029+ launch window, making it a manageable competitive headwind rather than an existential threat to Novo/Lilly's obesity franchises."
The article conflates a modest phase 2b win with competitive threat, but the math doesn't support the panic. Pfizer's 15.9% weight loss at 32 weeks trails Novo's Wegovy (22%+) and Lilly's Zepbound (21%+) by material margins—monthly dosing is convenience, not efficacy. More critically: Pfizer won't launch until 2029 at earliest, by which time Novo and Lilly will have multi-year head starts on supply chains, payer relationships, and brand loyalty in a market already showing saturation signals (Novo's obesity growth slowed to 26% YoY from prior 40%+ rates). The article ignores that 'pricing power erosion' assumes Pfizer gains meaningful share—but inferior efficacy + late entry + crowded pipeline (20+ programs = unfocused R&D) makes that speculative.
Monthly dosing could genuinely shift patient compliance and drive unexpected market share gains despite lower absolute weight loss; and Pfizer's scale/distribution might compress timelines or enable rapid uptake once approved.
"Pfizer's vaccine logistics could shorten the manufacturing timeline others treat as fixed."
Gemini flags manufacturing scale as decisive, yet ignores Pfizer's existing cold-chain infrastructure from its vaccine portfolio, which could compress the supply ramp once phase 3 data clears. This creates an unmentioned pathway for faster share capture than the 2029+ consensus implies. Still, inferior 15.9% weight loss leaves little margin for error if adherence gains prove modest in real-world use.
"Pfizer's potential supply advantage won't offset an efficacy gap and payer hurdles; upside hinges on Phase 3 results, not logistics alone."
Gemini overemphasizes supply chain gains; even with Pfizer's cold-chain assets, the business risk isn't inventory, it's real-world efficacy and payer acceptability. 15.9% weight loss at 32 weeks is well below Wegovy/Novo's 21-22%, which means a harder path to price power and coverage, regardless of monthly dosing. If Phase 3 durability or safety flags surface, the supposed ramp collapses. Manufacturing scale is necessary but not sufficient.
"Patient adherence via monthly dosing is a more significant competitive moat than the marginal efficacy gap between Pfizer and the current duopoly."
Claude, your focus on efficacy as the primary barrier ignores the history of chronic disease management. Patients often prioritize convenience over maximal efficacy, as seen in the transition from daily to weekly injectables. If Pfizer’s 15.9% is 'good enough' to hit the metabolic sweet spot, the monthly dosing interval will be the primary driver of market share, not a secondary feature. The real risk isn't efficacy; it's the potential for unforeseen safety signals in Phase 3.
"Convenience matters in chronic disease, but not enough to offset a 25% efficacy gap without hard real-world adherence data Pfizer hasn't shown yet."
Gemini's convenience-over-efficacy framing deserves scrutiny. Daily-to-weekly transitions worked because efficacy was comparable or superior; here, 15.9% vs. 21-22% is a 25% relative gap. History shows payers won't cover 'good enough' drugs at premium pricing when superior alternatives exist. Monthly dosing alone doesn't overcome that math unless real-world adherence data—absent from phase 2b—proves dramatic compliance gains. That's the unproven assumption everyone's skating past.
The panel is neutral on Pfizer's berobenatide, with key concerns being its inferior efficacy compared to competitors and the significant time gap before potential market entry.
Monthly dosing could drive adherence and market share if real-world data supports significant compliance gains.
Inferior efficacy and late entry may hinder Pfizer's ability to capture meaningful market share.